Vir Biotechnology, Inc. Depreciation
Vir Biotechnology, Inc. (VIR) reported Depreciation of $2.70 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-05
- Vir Biotechnology, Inc. depreciation for the quarter ending 2026-06-30 was $2.70M, a 6.90% decline year-over-year.
- Vir Biotechnology, Inc. depreciation for the quarter ending 2026-03-31 was $2.70M, a 3.57% decline year-over-year.
- Vir Biotechnology, Inc. depreciation for the quarter ending 2025-12-31 was $2.80M, a 3.70% increase year-over-year.
- Vir Biotechnology, Inc. depreciation for the quarter ending 2025-09-30 was $2.90M, a 0.00% change year-over-year.
- Vir Biotechnology, Inc. depreciation for fiscal 2025 was $11.40M, a 19.72% decline from fiscal 2024.
- Vir Biotechnology, Inc. depreciation for fiscal 2024 was $14.20M, a 24.87% decline from fiscal 2023.
- Vir Biotechnology, Inc. depreciation for fiscal 2023 was $18.90M, a 200.00% increase from fiscal 2022.
- Vir Biotechnology, Inc. depreciation for fiscal 2022 was $6.30M.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.70M 10-Q · filed 2026-08-05 | $5.40M 10-Q · filed 2026-08-05 | $8.20M derived: sum of 3 quarters · filed 2026-08-05 | $11.10M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $2.70M 10-Q · filed 2026-05-07 | $5.50M derived: sum of 2 quarters · filed 2026-05-07 | $8.40M derived: sum of 3 quarters · filed 2026-05-07 | $11.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $2.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $5.70M derived: sum of 2 quarters · filed 2026-02-23 | $8.60M derived: sum of 3 quarters · filed 2026-08-05 | $11.40M 10-K · filed 2026-02-23 |
| 2025-09-30 | $2.90M 10-Q · filed 2025-11-05 | $5.80M derived: sum of 2 quarters · filed 2026-08-05 | $8.60M 10-Q · filed 2025-11-05 | $11.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $2.90M 10-Q · filed 2026-08-05 | $5.70M 10-Q · filed 2026-08-05 | $8.40M derived: sum of 3 quarters · filed 2026-08-05 | $11.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $2.80M 10-Q · filed 2026-05-07 | $5.50M derived: sum of 2 quarters · filed 2026-05-07 | $8.40M derived: sum of 3 quarters · filed 2026-05-07 | $12.60M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $5.60M derived: sum of 2 quarters · filed 2026-02-23 | $9.80M derived: sum of 3 quarters · filed 2026-02-23 | $14.20M 10-K · filed 2026-02-23 |
| 2024-09-30 | $2.90M 10-Q · filed 2025-11-05 | $7.10M derived: sum of 2 quarters · filed 2025-11-05 | $11.50M 10-Q · filed 2025-11-05 | $15.80M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $4.20M 10-Q · filed 2025-08-06 | $8.60M 10-Q · filed 2025-08-06 | $12.90M derived: sum of 3 quarters · filed 2026-02-23 | $17.40M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $4.40M 10-Q · filed 2025-05-08 | $8.70M derived: sum of 2 quarters · filed 2026-02-23 | $13.20M derived: sum of 3 quarters · filed 2026-02-23 | $17.80M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.80M derived: sum of 2 quarters · filed 2026-02-23 | $13.40M derived: sum of 3 quarters · filed 2026-02-23 | $18.90M 10-K · filed 2026-02-23 |
| 2023-09-30 | $4.50M 10-Q · filed 2024-11-04 | $9.10M derived: sum of 2 quarters · filed 2024-11-04 | $14.60M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $4.60M 10-Q · filed 2024-08-01 | $10.10M 10-Q · filed 2024-08-01 | ||
| 2023-03-31 | $5.50M 10-Q · filed 2024-05-03 | |||
| 2022-12-31 | $6.30M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |